Lilly and Regeneron have asked the U.S. Food and Drug Administration to grant emergency use authorization for their drugs for Covid-19 while late-stage studies continue.
Earlier in October, the trial's data-safety monitors recommend the pause, but didn't recommend pausing another government-run trial, known as ACTIV-2.
"Lilly has leveraged our deep scientific capability to fight this pandemic, and we are proud of our efforts to develop potential medicines to combat COVID-19", Eli Lilly's CEO, David Ricks, said in a statement.
On Monday, the National Institutes of Health, which sponsored the trial, found the antibody treatment posed no significant safety risks for patients.
The examine aimed to judge whether or not Eli Lilly and Co.'s antibody remedy was efficient in folks hospitalized for COVID-19 who had been additionally receiving remdesivir, the antiviral drug developed by Gilead Sciences. There were hints the drug might help avoid hospitalisation, but more study is needed.
Lilly is codeveloping the drug with AbCellera Biologics Inc., of Vancouver, Canada, which isolated antibodies from a blood sample taken from one of the earliest Americans to recover from Covid-19.
The blood of COVID-19 survivors, known as convalescent plasma, is now being tested as a treatment for patients because it contains these antibodies.
Lilly said Monday all other studies of LY-CoV555 are still ongoing, including in nonhospitalized patients and residents and staff at long-term care facilities.
The experimental drugs are concentrated versions of one or two specific antibodies that worked best against the coronavirus in lab and animal tests.
The drugmaker said Tuesday it remains confident that its drug may stop COVID-19 from developing in other patients.
If its drug is approved for emergency use by the FDA, Eli Lilly said, it will have 100,000 vials ready to ship within days.
The Indianapolis-based drug maker logged a third-quarter profit of $1.21 billion, or $1.33 a share, compared with a profit of $1.25 billion, or $1.37 a share, in the same three-month period a year earlier.
According to Reuters, Lilly said it expects COVID-19 research and development this year to cost around $400 million, which led to shared dropping four percent before the opening bell.